1 unchanged sentence
Trading Plans
−Removed: During the period from February 27, 2023, to March 31, 2023, our Section 16 officers and directors adopted or terminated contracts, instructions or written plans for the purchase or sale of our securities as noted below:
+Added: During the three months ended June 30, 2023, our Section 16 officers and directors adopted or terminated contracts, instructions or written plans for the purchase or sale of our securities as noted below:
Action Date Trading Arrangement Total Shares to be Sold Expiration Date
Rule 10b5-1* Non-Rule 10b5-1**
−Removed: Robert Blanks, Chief Regulatory and Quality Assurance Officer Adoption March 24, 2023 X 45,748 December 15, 2023
−Removed: Elizabeth Grammer, Esq.
−Removed: Chief Legal and Administrative Officer Adoption March 24, 2023 X 100,000 December 15, 2023
−Removed: Laura Williams, M.D., M.P.H., Chief Medical Officer Adoption March 24, 2023 X 128,876 December 15, 2023
+Added: David Rosenbaum , Chief Development Officer
+Added: Adoption June 9, 2023 X 95,832 March 15, 2024
*Intended to satisfy the affirmative defense of Rule 10b5-1(c)
2 unchanged sentences
Number Exhibit Description Form Date Number Filed
−Removed: 10.1 Open Market Sale Agreement S M , dated January 18, 2023, by and between Ardelyx, Inc.
−Removed: and Jefferies LLC.
−Removed: S-3 1/19/2023 1.2
−Removed: 10.2 Second Amendment to Loan and Security Agreement dated February 9, 2023, by and between Ardelyx, Inc.
−Removed: and SLR Investment Corp.
−Removed: 10-K 3/2/2023 10.24(c)
−Removed: 10.3 First Amendment to the Manufacturing Services Agreement dated February 27, 2023, between Ardelyx, Inc.
−Removed: and Patheon Pharmaceuticals Inc.
−Removed: 10-K 3/2/2023 10.27(b)††
+Added: 3.1 Certificate of Amendment to Amended and Restated Certificate of Incorporation of Ardelyx, Inc.
+Added: 8-K 6/20/2023 3.1
31.1 Certification of Chief Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
2 unchanged sentences
101 The following financial statements, formatted in Inline Extensible Business Reporting Language (XBRL):
−Removed: (i) Condensed Balance Sheets as of March 31, 2023 and December 31, 2022, (ii) Condensed Statements of Operations and Comprehensive Loss for the three months ended March 31, 2023 and 2022, (iii) Condensed Statements of Cash Flows for the three months ended March 31, 2023 and 2022, and (iv) Notes to Unaudited Condensed Financial Statements.
+Added: (i) Condensed Balance Sheets as of June 30, 2023 and December 31, 2022, (ii) Condensed Statements of Operations and Comprehensive Loss for the three and six months ended June 30, 2023 and 2022, (iii) Condensed Statements of Cash Flows for the three and six months ended June 30, 2023 and 2022, and (iv) Notes to Unaudited Condensed Financial Statements.
104 Cover Page Interactive Data File, formatted in Inline XBRL and contained in Exhibit 101.
−Removed: †† Certain portions of this exhibit have been redacted pursuant to Item 601(b)(10) of Regulation S-K.
−Removed: A copy of the omitted portions will be furnished supplementally to the Securities and Exchange Commission upon request.
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
Ardelyx, Inc.
−Removed: May 3, 2023 By:
+Added: August 2, 2023 By:
/s/ Robert Felsch
3 unchanged sentences
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.